UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial

医学氟达拉滨阿勒姆图祖马细胞因子释放综合征内科学微小残留病嵌合抗原受体环磷酰胺耐火材料（行星科学）不利影响累积发病率临床研究阶段胃肠病学临床试验肿瘤科免疫学移植化疗免疫疗法白血病癌症天体生物学物理

作者

Reuben Benjamin,Nitin Jain,Marcela V. Maus,Nicolas Boissel,Charlotte Graham,Agnieszka Jóźwik,Deborah Yallop,Marina Konopleva,Matthew J. Frigault,Takanori Teshima,Koji Kato,Floriane Boucaud,Svetlana Balandraud,Athos Gianella-Borradori,Florence Binlich,Ibtissam Marchiq,Sandra Dupouy,Maria Almena-Carrasco,Matthieu Pannaux,Sylvain Fouliard,Éolia Brissot,Mohamad Mohty,Reuben Benjamin,Charlotte Graham,Agnieszka Jóźwik,Deborah Yallop,Laarni Bonganay,Lorraine Catt,Jackie Chappell,Gary Cheung,Vicky Chu,Kirsty Cuthill,Steven Devereux,Alan Dunlop,Rose Ellard,Farzin Farzeneh,Najeem Folarin,Elka Giemza,Shireen Kassam,Majid Kazmi,Andrea Kühnl,Jen Lewis,M.Yu. Liskova,Alice Mason,Victoria Metaxa,Ghulam Mufti,Helena Munro,Antonio Pagliuca,Piers Patten,Victoria Potter,Carmel Rice,Adeel Saleem,Robin Sanderson,Orla Stewart,Elias Jabbour,Nitin Jain,Emily Jones,Hagop M. Kantarjian,Partow Kebriaei,Marina Konopleva,Kara McGee,William G. Wierda,Jami Brown,Keagan S. Casey,Matthew J. Frigault,Hanno Hock,Richard Mathews,Marcela V. Maus,Meaghan A McKeown,Thomas R. Spitzer,Vesselina Toncheva,Élie Azoulay,Nicolas Boissel,Sophie Caillat‐Zucman,Karine Celli‐Lebras,Emmanuelle Clappier,Raphaël Itzykson,Jérôme Larghero,Étienne Lengliné,Isabelle Madelaine,Martine Meunier,Florence Rabian,Emmanuel Raffoux,Marie-Thérèse Tremorin,Agnès Bonnin,Éolia Brissot,Anne Daguenel-Nguyen,Rémy Duléry,Tounes Ledraa,Florent Malard,Clémence Mediavilla,Mohamad Mohty,Anne Vekhoff,Takanori Teshima,Koji Kato

出处

期刊：The Lancet Haematology [Elsevier]
日期：2022-10-10 卷期号：9 (11): e833-e843 被引量：61

链接

nih.govdoi.org

标识

DOI：10.1016/s2352-3026(22)00245-9

摘要

The prognosis for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia remains poor. UCART19, an allogeneic genome-edited anti-CD19 chimeric antigen receptor (CAR) T-cell product derived from healthy donors and available for immediate clinical use, offers a potential therapeutic option for such patients. The CALM trial is a first-in-human study evaluating the safety and antileukaemic activity of UCART19 in adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia.

求助该文献

最长约 10秒，即可获得该文献文件

UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial

今日热心研友